ASX ANNOUNCEMENT

11 July 2022

Update on FIH DurAVR™ THV Study

Brisbane, Australia and Minneapolis, USA, Anteris Technologies Ltd (ASX: AVR) reports the 30-day follow-up results on the second cohort of (eight) patients showed clinically significant improvements.

Specifically, there was an average 81% decline in Mean Pressure Gradient (range, -89% to -74%) with an average 300% increase in EOA (effective orifice area) (range, 217%-582%), denoting a marked improved in the valve’s surface area and, hence, improved blood flow.

Furthermore, we continue to observe best-in-class laminar flow and improved (normalized) pressures under high cardiac output conditions.

All thirteen patients in this first-in-human DurAVR™ THV study (performed at the Tbilisi Heart and Vascular Clinic, Tbilisi, Georgia) continue to show marked improvements in their clinical status compared with pretreatment levels. The study will continue to be reported on at the 12-month mark.

Highlights:

• Outstanding haemodynamics despite complex anatomy
• The ComASUR™ delivery system performed as expected allowing accurate valve placement
• Outstanding laminar flow
• Excellent improvement in quality-of-life markers (including 6-minute walk test)
• No thrombus on CT

“We continue to be excited about the superior haemodynamic performance of the DurAVR™ system despite small annuli and complex anatomy. Its remarkable flow characteristics are as close to a normal human aortic valve as we have seen, a testament to the unique 3D tissue design,” Anteris CMO, Dr Chris Meduri, said.

“The data so far is extremely encouraging and fulfilling the hypothesis that DurAVR™ works better and lasts longer. As we move into the second half, we will continue enrolling patients into our studies (Europe and FDA EFS) and gathering data for presentation at the major conferences as well as regulatory filings throughout the rest of the year. We will continue generating non-patient data as well with leading research institutions that demonstrate DurAVR’s™ superior flow characteristics compared with competitor valves as well as other relevant data,” Anteris CEO, Wayne Paterson, added.

ENDS
About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd is a structural heart company that delivers clinically superior and durable solutions through better science and better design.

Its focus is developing next-generation technologies that help healthcare professionals reproduce consistent life-changing outcomes for patients.

Anteris’ DurAVR™ 3D single-piece aortic heart valve replacement addresses the needs of tomorrow’s younger and more active aortic stenosis patients by delivering superior performance and durability through innovations designed to last the remainder of a patient’s lifetime.

The proven benefits of its patented ADAPT® tissue technology, paired with the unique design of our DurAVR™ 3D single-piece aortic heart valve, have the potential to deliver a game-changing treatment to aortic stenosis patients worldwide and provide a much-needed solution to the challenges facing doctors today.

Authorisation and Additional information

This announcement was authorised by the Board of Directors.

For more information:

Hannah Howlett
WE Communications
E: WE-AUAnterisTech@we-worldwide.com
P: +61 4 5064 8064
www.anteristech.com
Twitter: @AnterisTech
Facebook: www.facebook.com/AnterisTech
LinkedIn: https://www.linkedin.com/company/anteristech